CARsgen Therapeutics reports significant share buyback activity

CARsgen Therapeutics Holdings Limited announced a significant repurchase of 168,000 ordinary shares on November 20, 2025, which are being held as treasury shares. The repurchase was executed on the Exchange at a volume-weighted average price of HK$17.7046 per share, with prices ranging from HK$17.54 to HK$17.85. The aggregate price paid for these repurchased shares totaled HK$2,974,372.8.

This transaction resulted in a decrease in the number of issued shares (excluding treasury shares) by 168,000, bringing the new balance to 574,806,905 shares. Concurrently, the number of treasury shares increased to 3,135,500. The repurchase represents 0.029% of the existing number of issued shares (excluding treasury shares) prior to the event.

The company’s repurchase mandate, approved on May 22, 2025, authorized the repurchase of up to 57,543,590 shares. To date, CARsgen Therapeutics has repurchased 3,590,500 shares on the Exchange, representing 0.624% of the issued shares (excluding treasury shares) as at the date of the resolution. The moratorium period for any issue of new shares or transfer of treasury shares after this repurchase extends until December 20, 2025.